Modelling the potential financial impacts of expanding access to immune checkpoint inhibitors as monotherapy for treating advanced non-small cell lung cancer
- DOI
- 10.1016/j.eclinm.2025.103261
- Published
- 2025-06
- Container
- eClinicalMedicine
- Publisher
- Elsevier BV
- Open access
- unknown
Credibility signals
uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- supportingDOI registered: A matching record was returned by Crossref.
- supportingDOI resolves: A matching record was returned by Crossref.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- supportingMetadata completeness: All 6 scored descriptive metadata groups are present.
Cite this work
BibTeX
@article{allodium:10.1016/j.eclinm.2025.103261,
title = {Modelling the potential financial impacts of expanding access to immune checkpoint inhibitors as monotherapy for treating advanced non-small cell lung cancer},
author = {Kiu Tay-Teo and Dario Trapani and Manju Sengar and Zeba Aziz and Filip Meheus and André Ilbawi and Elisabeth G.E. de Vries and Lorenzo Moja},
year = {2025},
journal = {eClinicalMedicine},
doi = {10.1016/j.eclinm.2025.103261},
url = {https://doi.org/10.1016/j.eclinm.2025.103261}
}RIS
TY - JOUR TI - Modelling the potential financial impacts of expanding access to immune checkpoint inhibitors as monotherapy for treating advanced non-small cell lung cancer AU - Kiu Tay-Teo AU - Dario Trapani AU - Manju Sengar AU - Zeba Aziz AU - Filip Meheus AU - André Ilbawi AU - Elisabeth G.E. de Vries AU - Lorenzo Moja PY - 2025 JO - eClinicalMedicine DO - 10.1016/j.eclinm.2025.103261 UR - https://doi.org/10.1016/j.eclinm.2025.103261 ER -
APA
Tay-Teo, K., Trapani, D., Sengar, M., Aziz, Z., Meheus, F., Ilbawi, A., Vries, E. G. D., & Moja, L. (2025). Modelling the potential financial impacts of expanding access to immune checkpoint inhibitors as monotherapy for treating advanced non-small cell lung cancer. eClinicalMedicine. https://doi.org/10.1016/j.eclinm.2025.103261
Source records
- crossref · retrieved 2026-09-27T07:47:52.136Z